Pact between the two is for identifying alternative therapeutic indications of marketed compounds for neglected diseases
New Delhi: GVK Biosciences on Wednesday said it has licensed its proprietary databases to the USFDA as part of a collaboration in drug repositioning to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.